SCHEMBL11944

SCHEMBL11944

CS(=O)(=O)C(CCC(N)=O)c1ccc(OCc2nc(-c3cccnc3)no2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
POLB P06746 1/20 0.53
PSMB5 P28074 2/20 0.48
KDM4E B2RXH2 1/20 0.48
PSMB8 P28062 1/20 0.47
ALDH1A1 P00352 1/20 0.46
KMT2A Q03164 1/20 0.46
TSHR P16473 3/20 0.45
ATM Q13315 1/20 0.45
LMNA P02545 1/20 0.45
FFAR1 O14842 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
TP53 P04637 2/20 0.44
MAPK1 P28482 2/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5861 0.90 FFAR1 (0.56) MAPTALDH1A1TSHRFFAR1SMN1; SMN2
SCHEMBL11942 0.81 PSMB5 (0.55) MAPTPOLBPSMB5KDM4EPSMB8
SCHEMBL11898794 0.80 ADAMTS4 (0.47) KMT2ASMN1; SMN2RAB9A
SCHEMBL5949 0.77 FFAR1 (0.38) MAPTTSHRFFAR1SMN1; SMN2RAB9A
SCHEMBL11328 0.76 SRC (0.41) MAPTLMNAFFAR1SMN1; SMN2
SCHEMBL6110 0.74 ADAM17 (0.49) MAPTPOLBKMT2ATSHRLMNA
SCHEMBL11943 0.74 FFAR1 (0.54) MAPTPOLBPSMB5KDM4EPSMB8
SCHEMBL5798 0.74 CYP27B1 (0.46)
SCHEMBL4107632 0.73 RAB9A (0.76) MAPTPOLBKDM4EALDH1A1KMT2A
SCHEMBL5959943 0.73 RAB9A (0.73) MAPTPOLBKDM4EALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents PFIZER INC. (US) 2014-12-11 US disclosed
US-8853258-B2 C-linked hydroxamic acid derivatives useful as antibacterial agents PFIZER INC. (US) 2014-10-07 US disclosed
EP-2488489-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc. (US) 2012-08-22 EP disclosed
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents BROWN MATTHEW FRANK (US) 2012-08-09 US disclosed
WO-2011045703-A2 C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202777-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents HAX1, LPXN, AGXT MAPT 4745/4885POLB 1774/4885PSMB5 2563/4885
US-20140364398-A1 C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents LCT, AGXT, PRXL2A MAPT 4708/4885POLB 2631/4885PSMB5 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.